Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

The new PDUFA target action date is April 29, 2025. Stealth BioTherapeutics Logo (PRNewsFoto/Stealth BioTherapeutics) (PRNewsfoto/Stealth BioTherapeutics) Stealth was notified last week that the ...

NEEDHAM, Mass., Jan. 23, 2025 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the ...

Credit: Shutterstock / Emily frost. US company Salubris Biotherapeutics (SalubrisBio) has seen its heart failure therapy, JK07, achieve some success in interim results taken from an ongoing Phase II ...

After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline of T-cell immunotherapies. Atara on Tuesday announced that the FDA has ...

CRL did not identify deficiencies related to clinical efficacy or safety data in the Biologics License Application (BLA), and the FDA did not request any new clinical studies to support approval ...

IT之家1 月 16 日消息，英伟达 GTC 2025 将于美国加州当地时间 3 月 17 日~21 日在圣何塞举行。而在本月 14 日，英伟达宣布将在今年度的 GTC 大会中首度引入“量子日”活动，该活动将在 3 月 20 日展开。 英伟达表示，今日计算机科学界在量子硬件、纠错和算法方面 ...

As partners Atara Biotherapeutics and Pierre Fabre Laboratories work to grow the reach of their novel T-cell immunotherapy Ebvallo, a manufacturing-related hitch has tripped up their ambition to la ...

--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative ...

Walmart steel cage match (although we would totally watch). Instead, Walmart gave its logo a makeover fit for modern times—at least that was the idea. But people, well, they have feelings.

Jan 16 (Reuters) - The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' (ATRA.O), opens new tab therapy to treat patients with a rare cancer that develops ...